Anika Therapeutics (ANIK) Cash from Financing Activities (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Cash from Financing Activities data on file, last reported at -$10.3 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$10.3 million, down 90.27% year-over-year; the trailing twelve-month figure through Mar 2026 was -$15.5 million (up 2.73% YoY), and the FY2025 annual result was -$10.6 million, up 17.11% from the prior year.
• Cash from Financing Activities declined to -$10.3 million in Q1 2026 per ANIK's latest filing, from -$5.3 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $667000.0 in Q4 2022 and troughed at -$10.3 million in Q1 2026.
• A 5-year average of -$2.6 million and a median of -$1.6 million in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities soared 1011.67% in 2022, then plunged 10645.65% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at $667000.0 in 2022, then sank by 48.73% to $342000.0 in 2023, then sank by 1665.5% to -$5.4 million in 2024, then advanced by 1.4% to -$5.3 million in 2025, then plunged by 96.0% to -$10.3 million in 2026.
• Business Quant data shows ANIK's Cash from Financing Activities at -$10.3 million in Q1 2026, -$5.3 million in Q4 2025, and -$13000.0 in Q3 2025.